Kamada (KMDA) Income from Continuing Operations (2012 - 2026)

Kamada (KMDA) posted quarterly Income from Continuing Operations of 6650000.0 for Q1 2026, down 28.2% year-on-year from 9262000.0 in Q1 2025, and up 12.6% on a QoQ basis from 5906000.0 in Q4 2025.

Kamada (KMDA) Income from Continuing Operations (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Income from Continuing Operations for 15 consecutive years, with 6650000.0 the latest figure, recorded in Q1 2026.

  • Quarterly Income from Continuing Operations fell 28.2% year-over-year to 6650000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20000328.0 (up 38.82% YoY) and the FY2025 annual result came in at 26736000.0, up 119.04% from the prior year.
  • Income from Continuing Operations improved to 6650000.0 in Q1 2026 per KMDA's latest filing, from 5906000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for KMDA reached as high as 9262000.0 in Q1 2025 and fell as low as 1809.0 in Q1 2023.
  • A 5-year average of 3292157.12 and a median of 3223000.0 in 2023 frame the typical range for Income from Continuing Operations.
  • The largest YoY upside for Income from Continuing Operations was 537066.67% in 2023 against a maximum downside of 100.1% in 2023.
  • Year by year, Income from Continuing Operations stood at 3247000.0 in 2022, then surged by 53.68% to 4990000.0 in 2023, then slumped by 77.76% to 1110000.0 in 2024, then surged by 432.07% to 5906000.0 in 2025, then increased by 12.6% to 6650000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods registered 6650000.0, 5906000.0, and 7438000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 370.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -3.58 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 274.90 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 57.00 Mn
10 Kamada 401.22 Mn 328.07 Mn 19.12 Mn 6.65 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 6.65 Mn
Dec 31, 2025 5.91 Mn
Sep 30, 2025 7.44 Mn
Jun 30, 2025 6,328.00
Mar 31, 2025 9.26 Mn
Dec 31, 2024 1.11 Mn
Sep 30, 2024 4.03 Mn
Jun 30, 2024 4,552.00
Mar 31, 2024 2.51 Mn
Dec 31, 2023 4.99 Mn
Sep 30, 2023 3.22 Mn
Jun 30, 2023 1.81 Mn
Mar 31, 2023 -1,809.00
Dec 31, 2022 3.25 Mn
Sep 30, 2022 600.00
Jun 30, 2022 3.95 Mn
Mar 31, 2022 1.83 Mn
Dec 31, 2021 -4.82 Mn
Sep 30, 2021 868,000.00
Jun 30, 2021 965,000.00